Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
In some patients, graft-induced dyskinesia develops following intrastriatal transplantation of embryonic neural tissue for the treatment of Parkinson's disease. The mechanisms underlying these involuntary movements need to be clarified before this approach to clinical cell therapy can be developed further. We previously found that rats with 6-OHDA lesions, primed with L-DOPA treatment and that have subsequently undergone intrastriatal graft surgery exhibit involuntary movements when subjected to amphetamine. This model of amphetamine-induced AIMs reflects a pattern of post-graft behaviours that in the absence of robust spontaneous GID in the rat is the closest approximation that we currently have available. We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery. We also demonstrate that neither changes in c-fos nor FosB/DeltaFosB expression in the lateral striatum are associated with the expression of these behaviours. Taken together, these data reveal that the severity of abnormal movements elicited by amphetamine in grafted animals may relate to previous L-DOPA exposure and dyskinesia development, but they develop through mechanisms that are independent of FosB/DeltaFosB upregulation.
Lane
E L
EL
Neuronal Survival Unit, Department of Experimental Medical Science, Lund, Sweden. LaneEL@Cardiff.ac.uk
Vercammen
L
L
Cenci
M A
MA
Brundin
P
P
D000661:Amphetamine / Q000633:toxicity*; D000818:Animals; D000978:Antiparkinson Agents / Q000633:toxicity; D016380:Brain Tissue Transplantation / Q000009:adverse effects* / Q000379:methods; D000697:Central Nervous System Stimulants / Q000633:toxicity; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D004357:Drug Synergism; D004409:Dyskinesia, Drug-Induced / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D007980:Levodopa / Q000633:toxicity*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000601:surgery; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D013565:Sympatholytics / Q000633:toxicity
D000978:Antiparkinson Agents; D000697:Central Nervous System Stimulants; D016760:Proto-Oncogene Proteins c-fos; D013565:Sympatholytics; D007980:Levodopa; D016627:Oxidopamine; D000661:Amphetamine